BDX · 10-Q · 2026Q2 · Full report

Operating Expense Trends

BECTON DICKINSON & CO · 2026-08-06 · Importance 31 · Surprise 32 · From source text

Selling and administrative expense increased to $1.261 billion in the third quarter from $1.163 billion, and to $3.703 billion for the first nine months from $3.435 billion. Selling and administrative expense represented 25.3% of quarterly revenue and 26.1% of nine-month revenue, up from 24.6% and 25.4%, respectively, because of higher selling, shipping and administrative costs, inflation and unfavorable foreign-currency translation. Third-quarter R&D expense increased as a percentage of revenue to 5.2% from 4.9%, reflecting project timing and increased product-development investment. Nine-month R&D expense remained 5.2% of revenue as project timing and cost containment offset higher investment.

Key facts

• Specified items presented for the three months ended June 30, 2026 totaled $1,986 million and $2,015 million for the three months ended June 30, 2025. source
• Purchase accounting adjustments in the nine-month period of 2025 were $1,481 million and in the nine-month period of 2026 were $1,113 million. source
• Effective October 1, 2025, BD reorganized its segment reporting structure into five distinct, separately-managed segments and eliminated the Life Sciences segment, resulting in four remaining worldwide segments: BD Medical Essentials, BD Connected Care, BD BioPharma Systems, and BD Interventional. source
• BD recorded charges of $75 million and $64 million to Other operating expense, net related to various legal matters in the nine-month periods of fiscal years 2026 and 2025, respectively. source

Impact estimates